|
News and project information on the Acomplia (Rimonabant) obesity treatment drug, developed by Sanofi-Aventis. ... Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works by blocking endogenous cannabinoid binding to neuronal...
|
www.drugdevelopment-technology.com/projects/rimonabant/
www.drugdevelopment-technology.com/projects/rimonabant/
|
|
|
|
Buy Rimonabant Acomplia online an anti obesity drug, Rimonabant is a miracle drug for effective weight management. Buy Rimonabant (acomplia) online in UK for permanent weight loss. ... A single pill Rimonabant has been found to stop food craving enough to help people lose weight, and could also help curb other unhealthy...
|
www.rimonabantonline.org/
www.rimonabantonline.org/
|
|
|
Rimonabant is a prescription cannabinoid receptor antagonist used by patients suffering from obesity as a measure complementary to a healthier diet and exercising. Rimonabant is efficient because of its ability to switch off the brain circuits that are known to cause cannabis-smokers to be very hungry.
|
|
|
|
Latest study confirms favorable effects of rimonabant Rio North America, but toxicity may be a problem ... At the recent American Heart Association Scientific Sessions 2004, new data were reported on the effectiveness of rimonabant for treating obesity. Rimonabant, an investigational drug from Sanofi-Aventis,
|
heartdisease.about.com/od/dietandobesity/a/rimonabant5....
heartdisease.about.com/od/dietandobesity/a/rimonabant5.htm
|
|
|
Rimonabant - a new drug for weight loss and smoking cessation ... Rimonabant - first of a new class of drugs ... Rimonabant is the first of a new class of drugs that block the cannabinoid receptor 1 (CB1). The CB1 receptor is thought to play an important role in certain aspects of human behavior and metabolism - specifically,
|
heartdisease.about.com/cs/riskfactors/a/rimonabant1.htm
heartdisease.about.com/cs/riskfactors/a/rimonabant1.htm
|
|
This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Aventis Inc., which is marketing it in Europe under the trademarked name Acomplia and in the United States under the trademarked name Zimulti.
|
Original Article from The New England Journal of Medicine -- Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia ... Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemi...
|
content.nejm.org/cgi/content/abstract/353/20/2121
|
|
They found that patients given rimonabant had a 4·7 kg greater weight reduction after one year than did those given placebo. However, patients given rimonabant were at 40% higher risk of having adverse events or serious adverse events.
|
www.drugs.com/clinical_trials/study-shows-weight-loss-r...
www.drugs.com/clinical_trials/study-shows-weight-loss-rimonabant-associated-severe-adverse-psychiatric-events-2745.html
|
|
